Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection
Status:
Completed
Trial end date:
2017-09-29
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability
of treatment with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in
treatment-naive and treatment-experienced participants with chronic genotype 1 hepatitis C
virus (HCV) infection.
Phase:
Phase 3
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Ledipasvir Ledipasvir, sofosbuvir drug combination Sofosbuvir